REFERENCES
  1. Ministry of Health Directorate-General for Public Health Guide to COVID-19. Scientific Advisory Board Study 2 August 2020
  2. Del Rio C, Malani P.N. COVID-19-New insights on a rapidly changing epidemic. J Am Med Assoc. 2020 Feb 28
  3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579 (7798): 270-273.
  4. YR Cao QD, Hong ZS, et al. The origin transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak an update on the status.  Mil Med Res. 2020; 7 (1): 11
  5. Huang C. Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020; 395 (10223): 497-506.
  6. Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. J Med Virol. 2020. 10.1002 / jmv.25763
  7. Liu Y, Mao B, Liang S, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J 2020; 55: 2001112
  8. Güneyli S, Atçeken Z, Doğan H, Altınmakas E, Atasoy KÇ. Radiological approach to COVID-19 pneumonia with an emphasis on chest CT. Diagn Interv Radiol 2020; 26:323–332.
  9. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019, novel coronavirus-infected pneumonia in Wuhan. China. JAMA. 2020, 323:1061–1069.
  10. Baloch S, Baloch MA, Zheng T, Pei X. The Coronavirus Disease 2019 (COVID-19) Pandemic. Tohoku J Exp Med. 2020 Apr;250(4):271-278.
  11. Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States. Diagnosis (Berl). 2020;7(2):91-6.
  12. Guneysu F, Yurumez Y, Guclu E, et al. The diagnostic process of COVID-19 in the emergency department: laboratory and ımaging methods. Revista da Associação Médica Brasileira , 2020,66: 2, 58-64
  13. Li R, Liu G, Huang X, et al. Dynamic changes in clinical and CT characteristics of COVID-19 cases with different exposure histories: a retrospective study. BMC Infect Dis. 2020 Aug 3;20(1):567.
  14. Akcay S, Ozlu T, Yilmaz A. Radiological approaches to COVID-19 pneumonia. Turk J Med Sci (2020) 50: 604-610
  15. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study. AJR Am J Roentgenol 2020; 1–6
  16. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 20:425–434
  17. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020 Feb 26
  18. Li X, Zeng X, Liu B, Yu Y. COVID-19 infection presenting with CT halo sign. Radiology 2020 Feb 12.
  19. Franquet T. Imaging of pulmonary viral pneumonia. Radiology 2011; 260:18-39
  20. Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020,395:497–506.
  21. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 382:1708–1720.
  22. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020 34:212–213.
  23. Zhonghua LX, Bing X, Za Z Epidemiology Working Group for Ncip Epidemic Response CCfDC. Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID19) in China. 2020. 41:145–151.
  24. Nishiura H, Kobayashi T, Miyama T. et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020, 94:154–155.
  25. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019. (COVID-19) cases on board the Diamond Princess cruise ship. Yokohama. Japan. 2020. Euro Surveill. 2020. 25:2000180.
  26. Ki M. Task Force for -nCo V. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. Epidemiol Health. 2020 42:e2020007.
  27. Lu X, Zhang L, Du H. et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 382:1663–1665.
  28. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility- king county. Washington. March 2020. MMWR Morb Mortal Wkly Rep. 2020, 69:377– 81.
  29. Sonmez O. Taşdemir ZA. Kara H V. Akçay S. Tobacco and COVID-19. Eurasian J Pulmonol 2020;22. Suppl S1:12-5.
  30. Morse JS, Lalonde T, Xu S, Liu W. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections Li et al. BMC Infectious Diseases (2020) 20:567 Page 13 of 14 caused by 2019-nCoV. Chembiochem. 2020;21(5):730–738.
  31. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci TrendsPublished online 28 January. 2020.
  32. Perego E, Callard F, Stras L, Melville-JÛhannesson B, Pope R, Alwan N. Why the Patient-Made Term ‘Long Covid’ is needed [version 1; peer review: awaiting peer review]. Wellcome Open Res. 2020;5,224.
  33. Greenhalgh T, Knight M, Buxton M, Husain L. Management of post-acute covid-19 in primary care. Bmj. 2020;370:m3026. 3.
  34. COVID Symptom Study. How long does COVID-19 last? (blog). London: Kings College London. https://covid.joinzoe.com/post/covid-long-term 2020. Accessed 1 Oct 2020
  35. Assaf G, Davis H, McCorkell L, (on behalf of the COVID-19 Body Politic Slack Group). An Analysis of the Prolonged COVID-19 Symptoms Survey by Patient-Led Research Team. Patient Led Res. 2020.https://patientresearchcovid19.com/
  36. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–5
  37. Arnold DT, Hamilton FW, Milne A, et al, Gunning S, Hatrick J, Hamilton S. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort. medRxiv. 2020.
  38. Goërtz YM, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6:00542–2020.
  39. Vaes AW, Machado FV, Meys R, et al.. Care dependency in nonhospitalized patients with COVID-19. J Clin Med. 2020;9(9):2946
  40. Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of ‘happy’ hypoxemia in COVID-19. Respir Res. 2020;21(1):198
  41. Ladds, E, Rushforth, A, Wieringa, S. et al.  Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Serv Res  2020, 20,  1144.
  42. Tenforde M, Kim S, Lindsell C, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020, ePub: 24 July 2020.
  43. Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2020;30
  44. Davido, B., Seang, S., Tubiana, R., & de Truchis, P. Post-COVID-19 chronic symptoms: a postinfectious entity? Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases , 2020, 26 (11), 1448–1449.
  45. Nikpouraghdam M, Jalali Farahani A, Alishiri G, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in Iran: a single center study. J Clin Virol. 2020;127:104378
  46. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol. 2019;56(3):308-21.
  47. Yao. Y, Cao. J, Wang Q. et al.  D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. j intensive care  2020, 8.  49